Clinical trials
IgA Nephropathy (IgAN) clinical trials
Below are recruiting iga nephropathy (igan) clinical trials, each written for real people, not researchers. We’re tracking 49 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07614477RecruitingPhase 2
Testing EVER001 for kidney protein-loss diseases
This study tests a new drug called EVER001 to see if it can reduce protein loss in urine and improve kidney function in patients with specific kidney diseases (FSGS, MCD, or IgAN). These are autoimmune kidney conditions that cause the kidneys to leak protein into the urine.
Beijing, Beijing MunicipalityAges 18–75 - NCT06792799RecruitingEarly Phase 1
CAR-NK cells for B-cell autoimmune diseases
This early phase trial tests a new treatment made from immune cells (CAR-NK cells) that target and destroy overactive B cells. It may help people with lupus, certain kidney diseases, or nephrotic syndrome that hasn't responded to standard therapies.
Hangzhou, ZhejiangAges 3 years+ - NCT07305116RecruitingPhase 1
CAR T-cell therapy for autoimmune diseases
This trial tests a new immune therapy called CAR T-cells that target two proteins (CD19 and BCMA) to treat autoimmune diseases like lupus, nephrotic syndrome, and others. It is for people whose standard treatments have not worked well enough.
Hangzhou, ZhejiangAges 3 years+ - NCT07507201RecruitingEarly Phase 1
Car-T cells for autoimmune diseases like lupus
This trial tests whether specially-engineered immune cells (CAR-T cells) can help people with certain autoimmune diseases that haven't gotten better with standard treatments. The cells are designed to target and remove faulty B cells that are causing the immune system to attack the body.
Hangzhou, ZhejiangAges 3 years+ - NCT07586267RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune blood diseases
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
Hangzhou, ZhejiangAges 3 years+ - NCT06674577Enrolling by invitationPhase 2
Long-term safety study of atacicept for IgA nephropathy
This study looks at the long-term safety and effectiveness of atacicept in people with IgA nephropathy (IgAN) who have already completed treatment in a previous atacicept study. It is for patients who want to continue their care and see how well the medicine works over more time.
Brisbane, CaliforniaAges 18–99 - NCT07182227RecruitingPhase 1/Phase 2
Gene therapy PS-002 for IgA nephropathy
This trial tests a new gene therapy called PS-002 for adults with IgA nephropathy. It aims to see if the treatment is safe and can help reduce protein loss in urine and protect kidney function.
Miami, FloridaAges 18 years+ - NCT07295808Recruiting
Study of IgA antibodies in kidney disease
This study looks at a specific type of antibody called IgA in patients with certain kidney diseases. It aims to understand which IgA antibodies cause kidney damage, which could help develop better treatments.
LimogesAges 18 years+ - NCT07750249Enrolling by invitationEarly Phase 1
Short-chain fatty acids for IgA nephropathy
This trial tests whether a daily supplement of short-chain fatty acids (SCFAs) can slow down kidney damage in people with IgA nephropathy. SCFAs are substances made by gut bacteria that may help reduce inflammation and protect the kidneys.
MartinAges 18 years+ - NCT03001947Recruiting
Study for people with biopsy-proven IgA kidney disease
This trial enrolls teens and adults with biopsy-proven IgA nephropathy to help doctors learn whether a specific care approach works better for high-quality treatment. It is meant for people whose IgA kidney disease is the primary form (not caused by another illness).
Guangzhou, GuangdongAges 14 years+ - NCT06797518RecruitingPhase 2
Testing iptacopan for IgA nephropathy kidney changes
This study tests if adding iptacopan to standard care can improve kidney health in adults with IgA nephropathy. You may qualify if you have a kidney biopsy confirming IgA nephropathy and your kidney function is stable enough.
Birmingham, AlabamaAges 18–99 - NCT06419205RecruitingPhase 2
ADX-097 for IgA nephropathy, lupus nephritis, or C3G
This study tests an experimental oral therapy called ADX-097 for people with three types of kidney disease: IgA nephropathy, lupus nephritis, or C3 glomerulopathy. The goal is to see if it’s safe and can help reduce kidney damage.
Lawrenceville, GeorgiaAges 16 years+ - NCT07541287RecruitingPhase 2
JADE101 for IgA Nephropathy Kidney Disease
This study tests whether JADE101, a new medicine, can help slow kidney damage in people with IgA nephropathy (a type of kidney disease caused by immune system problems). You'll take it alongside your current blood pressure medications for about 48 weeks.
Chula Vista, CaliforniaAges 18–60 - NCT07585981Recruiting
Budesonide capsules for IgA kidney disease
This trial tests whether a special steroid capsule called budesonide can help treat IgA nephropathy, a kidney disease where your immune system damages the kidneys. You would take this medication along with standard care to see if it slows kidney damage and reduces protein in your urine.
BeijingAges 18 years+ - NCT06740526RecruitingPhase 2
A trial of sibeprenlimab for IgA nephropathy kidney tissue
This study tests a drug called sibeprenlimab to see how it affects kidney tissue in people with IgA nephropathy (IgAN), a condition where antibodies build up in the kidneys. It may help protect your kidneys if your disease is still active.
Denver, ColoradoAges 16 years+ - NCT06994845RecruitingPhase 3
Testing iptacopan for children with IgA nephropathy
This study tests a new medicine called iptacopan to see if it helps children with IgA nephropathy (a kidney disease). Kids who join will receive the study treatment and be monitored for safety and effectiveness.
Aurora, ColoradoAges 2–18 - NCT07375758RecruitingPhase 1/Phase 2
Testing MIL116 in healthy people and those with IgA Nephropathy
This study tests a new drug called MIL116 for IgA Nephropathy. First, healthy volunteers will test the drug's safety, then people with IgA Nephropathy will see if it can help reduce protein in their urine.
BeijingAges 18 years+ - NCT07135219Enrolling by invitationEarly Phase 1
Study of cizutamig for IgA nephropathy
This trial tests a new drug called cizutamig for people with IgA nephropathy who still have high protein in their urine despite trying other treatments. It aims to see if the drug can help protect kidney function.
BeijingAges 18–75 - NCT07024563RecruitingPhase 3
Testing ravulizumab for kids with IgA nephropathy
This study tests a drug called ravulizumab for children aged 2 to under 18 with IgA nephropathy, a kidney condition. It aims to see if the drug can help protect the kidneys and reduce protein in the urine.
Palo Alto, CaliforniaAges 2–18 - NCT05510323RecruitingPhase 3
Immunosuppressive treatment for IgA kidney disease in stage 3–4
This trial tests whether immunosuppressive therapy (medicine that calms the immune system) helps people with IgA nephropathy and moderately to severely reduced kidney function. It is intended for adults with confirmed IgA kidney disease who still have significant protein in the urine despite standard blood-pressure kidney protection treatment.
Xi'anAges 18 years+ - NCT06858319RecruitingPhase 3
Long-term study of zigakibart for IgA nephropathy
This study is for people with IgA nephropathy who completed a previous zigakibart study. It tests whether continuing treatment with zigakibart (given as a shot every two weeks) is safe and helpful over a longer period.
Denver, ColoradoAges 18–100 - NCT06963827RecruitingPhase 3
Study of mezagitamab for IgA nephropathy
This trial tests a new drug called mezagitamab for adults with IgA nephropathy, a kidney condition. The study aims to see if this drug can help reduce protein in the urine and preserve kidney function. You may be eligible if your kidney function is above a certain level and your urine protein is high enough.
Birmingham, AlabamaAges 18 years+ - NCT07203404RecruitingEarly Phase 1
A study of a universal CAR-T cell therapy for autoimmune diseases
This trial tests a new treatment called RD06-05, which uses specially engineered immune cells to target and potentially reset parts of the immune system that are attacking your own body. It is being studied for several autoimmune conditions like lupus, vasculitis, kidney diseases, and more.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05003986RecruitingPhase 2
Sparsentan for children with protein leaking kidney diseases
This Phase 2 study tests sparsentan in children with certain kidney diseases that cause high amounts of protein in the urine. It aims to see if the medicine can reduce kidney damage signals and protein leakage compared with standard care.
Los Angeles, CaliforniaAges 1–17
Hear when a new IgA Nephropathy (IgAN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for iga nephropathy (igan)?
- Yes. Clin2 currently lists 49 recruiting iga nephropathy (igan) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a iga nephropathy (igan) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a iga nephropathy (igan) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.